These analyses indicate that ZMYND8 overexpression in MDA-MB-231 cells treated with doxorubicin significantly alters the tumor/cancer-related gene levels and signaling pathways specific to aggressive breast cancer, and suggests the role of ZMYND8 in chemo-resistance. This evidence concerns the gene ZMYND8 and breast carcinoma.